Title |
The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro
|
---|---|
Published in |
BMC Veterinary Research, January 2013
|
DOI | 10.1186/1746-6148-9-15 |
Pubmed ID | |
Authors |
Kevin Marley, Stuart C Helfand, Wade A Edris, John E Mata, Alix I Gitelman, Jan Medlock, Bernard Séguin |
Abstract |
Osteosarcoma (OS) affects over 8000 dogs/year in the United States. The disease usually arises in the appendicular skeleton and metastasizes to the lung. Dogs with localized appendicular disease benefit from limb amputation and chemotherapy but most die within 6-12 months despite these treatments. Taurolidine, a derivative of taurine, has anti-tumor and anti-angiogenic effects against a variety of cancers. The following in vitro studies tested taurolidine as a candidate for adjuvant therapy for canine OS. Tests for p53 protein status and caspase activity were used to elucidate mechanisms of taurolidine-induced cell death. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 40% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 2% |
South Africa | 1 | 2% |
Unknown | 49 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 20% |
Student > Postgraduate | 10 | 20% |
Other | 6 | 12% |
Student > Bachelor | 4 | 8% |
Student > Ph. D. Student | 3 | 6% |
Other | 11 | 22% |
Unknown | 7 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 35% |
Veterinary Science and Veterinary Medicine | 17 | 33% |
Agricultural and Biological Sciences | 5 | 10% |
Nursing and Health Professions | 1 | 2% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Other | 2 | 4% |
Unknown | 7 | 14% |